Taken together, these findings suggest that the SPHK1 signaling axis is an innovative therapeutic target for managing patients with IPF and other forms of lung fibrosis by ameliorating AEC mtDNA damage and Mo-AM recruitment. The gene discussed is SPHK1; the disease is pulmonary fibrosis.